Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

作者：Ítalo Faria do Valle, Thomas Grinda, Lorenzo Antonuzzo, Barbara Pistilli · 发表于：npj Breast Cancer · 年份：2025 · DOI：10.1038/s41523-025-00829-5 · 被引用次数：30 · 研究领域：HER2/EGFR in Cancer Research、Monoclonal and Polyclonal Antibodies Research、Estrogen and related hormone effects

Although antibody-drug conjugates (ADCs) revolutionized cancer treatment, especially in breast cancer, resistance remains a major challenge. It may involve target expression and distribution, linker stability, ADC intratumor penetration and intracellular internalization, payload activity but also interaction with the tumor microenvironment. Strategies to overcome resistance under investigation include combination therapies, novel payloads, and next-generation ADC designs. The identification of predictive biomarkers may also help guide treatment selection and prevent resistance.